Table 1

Baseline characteristics

VariableTreatment escalation (n=15)Non-escalation (n=26)Total (n=41)P value
Age, years (mean, SD)60.1 (10.6)53.7 (13.8)55.8 (13.2)<0.0001*
Female, n (percentage of patients)5 (33%)15 (58%)20 (49 %)<0.0001*
Months with diagnosis (median, IQR)16 (2, 52)51 (14, 114)44 (13, 87)<0.0001*
NT-proBNP (median, IQR)51 (22.2, 359)27.2 (8, 65,2)34 (14.4, 160)<0.0001*
6MWD (mean, SD)403 (130.6)511.3 (105)475.2 (125.1)<0.0001*
WHO-FC, n
 I055<0.0001*
 II41317
 III9716
 IV213
 WHO-FC (mean, SD)2.8 (0.9)2.2 (0.7)2.4 (0.8)
Echocardiography
 TRI, mm Hg (mean, SD)63.2 (22.1)43.8 (14.9)50.3 (19.9)<0.0001*
 TAPSE, cm1.8 (0.4)2.2 (0.3)2.1 (0.4)<0.0001*
 RVESV, mL86.6 (57.2)50.8 (31.2)62.1 (44.4)<0.0001*
 RVEDV, mL129.3 (62.8)88 (40.5)101 (52.3)<0.0001*
 Right atrial area (cm2)27.3 (11.1)20.5 (7.7)22.6 (9.5)<0.0001*
CMR
 RVEF, %36.9 (12.2)49.8 (10.6)45.5 (12.7)<0.0001*
 RVEDV, mL139.1 (54.3)95.4 (35.5)109.9 (47.4)<0.0001*
 RVESV, mL168.4 (91.9)100.1 (64.2)122.7 (81.2)<0.0001*
  • Patient demographics at baseline including echocardiography and CMR scans according to treatment group. Values are presented as means and medians.12

  • CMR, cardiac magnetic resonance; 6MWD, 6-min walking distance; NT-proBNP, N-terminal brain natriuretic in pmol/L; RVEDV, right ventricle end-diastolic volume; RVEF, right ventricle ejection fraction; RVESV, right ventricle end-systolic volume; TAPSE, tricuspid annular plane systolic excursion; TRI, tricuspid regurgitation; WHO FC, WHO functional classification.